Host: Mark A. Socinski, MD

Guest: Alexander Drilon, MD

There are now multiple biomarker-defined patient subgroups in advanced non-small cell lung cancer (NSCLC), including RET rearrangements, and there is growing evidence that treatment with targeted therapies has significant clinical outcomes. In response to current rapid changes in the field of NSCLC, Drs. Mark Socinski and Alexander Drilon discuss the biology of RET fusion and how to translate the latest recommendations for targeted therapies into clinical practice.

Since this CME activity has been published the FDA has approved a new treatment for adults with metastatic RET fusion-positive non-small cell lung cancer. To learn more about this approval, please visit the FDA.gov: FDA approves pralsetinib for lung cancer with RET gene fusions